Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-30335
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFröhlich, Fabienne-
dc.contributor.authorMicheroli, Raphael-
dc.contributor.authorHebeisen, Monika-
dc.contributor.authorKissling, Seraphina-
dc.contributor.authorBürki, Kristina-
dc.contributor.authorExer, Pascale-
dc.contributor.authorBräm, René-
dc.contributor.authorNiedermann, Karin-
dc.contributor.authorMöller, Burkhard-
dc.contributor.authorNissen, Michael J.-
dc.contributor.authorKyburz, Diego-
dc.contributor.authorAndor, Michael-
dc.contributor.authorDistler, Oliver-
dc.contributor.authorScherer, Almut-
dc.contributor.authorCiurea, Adrian-
dc.date.accessioned2024-03-22T10:33:26Z-
dc.date.available2024-03-22T10:33:26Z-
dc.date.issued2023-05-
dc.identifier.issn0770-3198de_CH
dc.identifier.issn1434-9949de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/30335-
dc.descriptionErworben im Rahmen der Schweizer Nationallizenzen (http://www.nationallizenzen.ch)de_CH
dc.description.abstractObjective: To explore the impact of the human leucocyte antigen (HLA)-B27 on the effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). Methods: A total of 1109 patients with available HLA-B27 status (831 B27+ patients and 278 B27− patients) fulfilling the Assessment of Spondyloarthritis international Society classification criteria for axSpA from the prospective Swiss Clinical Quality Management Registry initiating a first TNFi were included. Drug retention was investigated with multiple adjusted Cox proportional hazard models with imputation of missing values. Multiple-adjusted logistic regression analyses were used to assess the proportion of patients reaching 50% reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) at 1 year. Results: B27+ and B27− patients differed with regard to age, sex, BASDAI, C-reactive protein (CRP), body mass index, enthesitis, uveitis, and classification status. After adjustment for potential confounders for the relationship between HLA-B27 and drug effectiveness (sex and family history of spondyloarthritis), a higher risk of drug discontinuation was found in B27− patients (HR 1.53, 95% CI 1.27–1.83). This difference decreased after additional adjustment for parameters which may act as mediators (HR 1.30, 95% CI 1.30–1.55). Male sex and elevated C-reactive protein (CRP) levels were consistently associated with longer retention. Comparable results were obtained for BASDAI50 responses. Conclusion: The HLA-B27 genotype is an important predictor of treatment effectiveness. Male sex and CRP seem, however, to better describe variability of response in individual patients. This data may help avoiding potential discrimination of B27− individuals with regard to TNFi initiation. Key Points: • HLA-B27 is a predictor of effectiveness of TNF inhibitors in axial spondyloarthritis. • Variability of response in individual patients is better defined by sex and objective markers of disease activity, such as C-reactive protein.de_CH
dc.language.isoende_CH
dc.publisherSpringerde_CH
dc.relation.ispartofClinical Rheumatologyde_CH
dc.rightshttps://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectAxial spondyloarthritisde_CH
dc.subjectHLA-B27de_CH
dc.subjectTNF inhibitionde_CH
dc.subjectTreatment responsede_CH
dc.subjectHumansde_CH
dc.subjectMalede_CH
dc.subjectTumor necrosis factor inhibitorde_CH
dc.subjectHLA-B27 antigende_CH
dc.subjectC-reactive proteinde_CH
dc.subjectSwitzerlandde_CH
dc.subjectProspective studyde_CH
dc.subjectRegistryde_CH
dc.subjectSpondylitis, ankylosingde_CH
dc.subjectSpondylarthritisde_CH
dc.subject.ddc616.7: Krankheiten des Bewegungsapparates und Orthopädiede_CH
dc.titleHLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis : data from the Swiss Clinical Quality Management Registryde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.organisationalunitInstitut für Physiotherapie (IPT)de_CH
dc.identifier.doi10.1007/s10067-022-06490-8de_CH
dc.identifier.doi10.21256/zhaw-30335-
dc.identifier.pmid36574181de_CH
zhaw.funding.euNode_CH
zhaw.issue5de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end1274de_CH
zhaw.pages.start1267de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume42de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
File Description SizeFormat 
2023_Froehlich-etal_HLA-B27-as-a-predictor-of-TNF-inhibitor-treatment-effectiveness.pdf907.98 kBAdobe PDFThumbnail
View/Open
Show simple item record
Fröhlich, F., Micheroli, R., Hebeisen, M., Kissling, S., Bürki, K., Exer, P., Bräm, R., Niedermann, K., Möller, B., Nissen, M. J., Kyburz, D., Andor, M., Distler, O., Scherer, A., & Ciurea, A. (2023). HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis : data from the Swiss Clinical Quality Management Registry. Clinical Rheumatology, 42(5), 1267–1274. https://doi.org/10.1007/s10067-022-06490-8
Fröhlich, F. et al. (2023) ‘HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis : data from the Swiss Clinical Quality Management Registry’, Clinical Rheumatology, 42(5), pp. 1267–1274. Available at: https://doi.org/10.1007/s10067-022-06490-8.
F. Fröhlich et al., “HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis : data from the Swiss Clinical Quality Management Registry,” Clinical Rheumatology, vol. 42, no. 5, pp. 1267–1274, May 2023, doi: 10.1007/s10067-022-06490-8.
FRÖHLICH, Fabienne, Raphael MICHEROLI, Monika HEBEISEN, Seraphina KISSLING, Kristina BÜRKI, Pascale EXER, René BRÄM, Karin NIEDERMANN, Burkhard MÖLLER, Michael J. NISSEN, Diego KYBURZ, Michael ANDOR, Oliver DISTLER, Almut SCHERER und Adrian CIUREA, 2023. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis : data from the Swiss Clinical Quality Management Registry. Clinical Rheumatology. Mai 2023. Bd. 42, Nr. 5, S. 1267–1274. DOI 10.1007/s10067-022-06490-8
Fröhlich, Fabienne, Raphael Micheroli, Monika Hebeisen, Seraphina Kissling, Kristina Bürki, Pascale Exer, René Bräm, et al. 2023. “HLA-B27 as a Predictor of Effectiveness of Treatment with TNF Inhibitors in Axial Spondyloarthritis : Data from the Swiss Clinical Quality Management Registry.” Clinical Rheumatology 42 (5): 1267–74. https://doi.org/10.1007/s10067-022-06490-8.
Fröhlich, Fabienne, et al. “HLA-B27 as a Predictor of Effectiveness of Treatment with TNF Inhibitors in Axial Spondyloarthritis : Data from the Swiss Clinical Quality Management Registry.” Clinical Rheumatology, vol. 42, no. 5, May 2023, pp. 1267–74, https://doi.org/10.1007/s10067-022-06490-8.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.